Comparative Pharmacology
Head-to-head clinical analysis: DRAX EXAMETAZIME versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAX EXAMETAZIME versus NEPHROSCAN.
DRAX EXAMETAZIME vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAX EXAMETAZIME is a diagnostic radiopharmaceutical composed of technetium-99m (Tc-99m) labeled to exametazime (hexamethylpropyleneamine oxime, HMPAO). It passively diffuses across the blood-brain barrier and is rapidly converted to a hydrophilic complex, which is trapped in brain tissue. Distribution is proportional to regional cerebral blood flow, allowing SPECT imaging of cerebral perfusion.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Adult: 5-20 mCi (185-740 MBq) administered intravenously as a single dose for brain imaging; dose is based on patient weight and imaging protocol.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal half-life is 6-8 hours; clinical context: allows for daily dosing in imaging studies.
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-65% unchanged; fecal: 35-50% as metabolites; total renal elimination accounts for ~70% of dose, with 30% undergoing biliary excretion.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical